Abstracts tagged "Epidemiologic methods and hyperuricemia"

Abstract Number: 2236 • 2015 ACR/ARHP Annual Meeting
Global Prevalence of Hyperuricemia: A Systematic Review of Population-Based Epidemiological Studies
Emma Smith¹ and Lyn March², ¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Sydney, Australia, ²Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia
Background/Purpose: Hyperuricemia, or raised serum uric acid (SUA), is the condition closely associated with gout due to the deposition of monosodium urate crystals in peripheral…
Abstract Number: 91 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Incident Hyperuricemia During Mid-Adulthood In African American and White Men and Women Enrolled In The Atherosclerosis Risk In Communities Study
Mara McAdams DeMarco¹, Andrew Law², Janet W. Maynard³, Josef Coresh¹ and Alan N. Baer⁴, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Epidemiology, Johns Hopkins, Baltimore, MD, ³Rheum/Mason F Lord Bldg/CtrTow, Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose : Increased serum urate levels are associated with poor outcomes including but not limited to gout. Better understanding of which patients are at risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].